Gilead Sciences | GILD - Loan Capital



Gilead Sciences reported $22.14B in Loan Capital for its fiscal quarter ending in June of 2025.


Loan Capital Change Date
AbbVie USD 64.53B 4.19B Mar/2025
Agios Pharmaceuticals USD 0 0 Mar/2025
ALKERMES USD 0 0 Mar/2025
Alnylam Pharmaceuticals USD 1.03B 956K Jun/2025
Amgen USD 53.76B 253M Jun/2025
Biogen USD 6.28B 1.74B Jun/2025
BioMarin Pharmaceutical USD 596.16M 512K Jun/2025
Bristol-Myers Squibb USD 44.47B 1.69B Jun/2025
Eli Lilly USD 34.18B 319.4M Jun/2025
Gilead Sciences USD 22.14B 6M Jun/2025
GlaxoSmithKline GBP 15.3B 1.17B Jun/2025
Glaxosmithkline GBP 15.3B 667M Jun/2025
Incyte USD 31.76M 883K Jun/2025
J&J USD 38.36B 7.7B Mar/2025
Merck USD 33.97B 484M Jun/2025
Moderna USD 32M 3M Jun/2025
Neurocrine Biosciences USD 0 0 Dec/2024
Novartis USD 24.06B 2.4B Jun/2025
Pfizer USD 57.5B 137M Jun/2025
PTC Therapeutics USD 2.13B 1.85B Jun/2025
Regeneron Pharmaceuticals USD 1.99B 719.7M Jun/2025
Sanofi 13.2B 211M Jun/2025
Sarepta Therapeutics USD 1.14B 1.17M Jun/2025
United Therapeutics USD 0 0 Mar/2025
Vertex Pharmaceuticals USD 112.8M 1.2M Dec/2024